Is Ceftriaxone-Induced Biliary Pseudolithiasis Influenced by UDP-Glucuronosyltransferase 1A1 Gene Polymorphisms? by Fretzayas, Andrew et al.
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2011, Article ID 730250, 3 pages
doi:10.1155/2011/730250
Case Report
Is Ceftriaxone-Induced Biliary Pseudolithiasis Inﬂuencedby
UDP-Glucuronosyltransferase1A1 Gene Polymorphisms?
Andrew Fretzayas,1 Olga Liapi,1 AnnaPapadopoulou,1 PolyxeniNicolaidou,1
andAlexandraStamoulakatou2
1Third Department of Pediatrics, “Attikon” General University Hospital, 1 Rimini Street, Haidari, 124 62 Athens, Greece
2Laboratory of Hematology, “Aghia Sophia” Children’s Hospital, Thivon and Papadiamantopoulou Street, Goudi,
115 27 Athens, Greece
Correspondence should be addressed to Andrew Fretzayas, afretz@med.uoa.gr
Received 11 June 2011; Accepted 22 August 2011
Academic Editor: Hermann E. Wasmuth
Copyright © 2011 Andrew Fretzayas et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Ceftriaxone (cfx), a third-generation cephalosporin antibiotic, leads to transient cholelithiasis in some children, also known as
pseudolithiasis. However, the underlying pathogenetic mechanism of this adverse eﬀect has not yet been elucidated. We describe 3
children with ceftriaxone-induced pseudolithiasis, who were also carriers of the A(TA)7TAA polymorphism of the UGT1A1 gene,
implying that a cause and eﬀect relation may exist.
1.Introduction
Cholelithiasis in childhood is usually considered a secondary
eﬀect of various predisposing factors such as hemolytic ane-
mia, hepatobiliary diseases, total parenteral nutrition, sepsis,
bowel resection, or a side eﬀect of certain medications [1,
2]. Among the latter, ceftriaxone (cfx), originally described
by Schaad et al. [3], has been recognized as a lithogenic
substance in a proportion of treated patients. In these
cases, ﬁne precipitations or sludge are formed temporarily,
resemblinggallstones.Theyresolveshortlyafterstoppingcfx,
and various terms, such as “pseudolithiasis” or “reversible
lithiasis”, have been used [4].
As the pathogenesis of cfx-induced pseudolithiasis is
currently unclear, and main predisposing factors, that is, the
drugandtheinfectionarecommoninallpatients,theanswer
mightbehiddeninthepatient’sgenomicdata.Weobserved3
children with cfx-induced pseudolithiasis who were also car-
riers of the A(TA)7TAA polymorphism of the UGT1A1 gene.
UGT1A1 encodes UDP-glucuronosyltransferase (UDPG),
an enzyme engaged in the glucuronidation pathway that
transforms small lipophilic molecules, (i.e., steroids, biliru-
bin, hormones, and drugs) into water-soluble, excretable
metabolites.
2. Case Presentation
Our 3 patients, consisting of one girl and two boys, aged
5,5 months, 18 months, and 4 years old, respectively,
were treated for urinary tract infection and received cfx
(100mg/kg/day)IVfor10–14 days.Onepatientalsoreceived
cefotaxime prior to cfx treatment. None had a history of
predisposing factors, a family history of gallstones, or was
treated with drugs associated with gallbladder lithiasis, such
as octreotide or furosemide.
All three patients developed gallbladder pseudolithia-
sis with typical sonographic appearance: intense, mobile,
echogenic material with acoustic shadow (Figure 1). They
were repeatedly screened with gallbladder ultrasound (US)
while on treatment, and follow-up examination was sched-
uled weekly until resolution of pseudolithiasis was seen.
Extensivelaboratoryinvestigationrevealednormalbloodcell
count without overt hemolysis, liver and renal function tests
within normal limits, as well as serum lipids and electrolytes.
Extensivedetailsofthepatients’datacanbefoundinTable 1.
Parents gave informed consent prior to the inclusion
of their children in the study. Genomic DNA for TA
insertion on the TATAA box of the UGT1A1 gene was
analyzed, as previously described [5]. Molecular analysis of2 Case Reports in Medicine
Table 1: Data about the clinical and family history and lab results (inﬂammation markers and liver function) of the patients.
Patient #1 Patient #2 Patient #3
Clinical complications
Pain Not referred Intense abdominal pain Not referred
Others Not referred Not referred Not referred
History of prolonged jaundice after birth Not referred Not referred Not referred
Family history of gallstones and Gilbert (Meulengracht disease) Not referred Not referred Not referred
Other genetic variations Not referred G6PD deﬁciency Not referred
Lab results
Inﬂammation markers
WBC (/μL) 16.170 18.240 14.690
NEUT-LYMPH-MONO (%) 94-4-2 65-29-6 48-43-3
CRP (mg/L) 15.5 19.9 45.90
Liver function
SGOT (U/L) 28 30 24
SGPT (U/L) 12 13 17
ALP 124 135 172
γGT (U/L) 9 14 10
TBIL (mg/dL) 0.41 0.3 0.2
DBIL (mg/dL) 0.13 0.11 0.1
WBC: white blood cell count, NEUT: neutrophils, LYMPH: lymphocytes, MONO: monocytes, CRP: C- reactive protein, SGOT: serum glutamic-oxaloacetic
transaminase, SGPT: serum glutamic-pyruvic transaminase, ALP: alkaline phosphatase, γGT: gamma-glutamyl transpeptidase, TBIL: total bilirubin, DBIL:
deconjucated bilirubin.
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Figure 1: Sonogram in one of our patients showing multiple
echogenic material with acoustic shadowing.
the TATAA-box-like sequence of the UGT1A1 promoter
revealed that two of the patients were heterozygous (TA7/
TA6) and one homozygous (TA7/TA7) for the polymorphism
in the TATAA box in the promoter region of the UGT1A1
gene. The study was approved by the appropriate ethics
committee and has therefore been performed in accordance
with the ethical standards.
3. Discussion
Although several prospective studies have evaluated the
incidence of transient gallbladder pseudolithiasis in patients
treatedwithcfx,theunderlyingpathogeneticmechanismhas
not been elucidated as yet [3, 4, 6]. Of interest, our children
with cfx-induced pseudolithiasis share a common denom-
inator that is hetero-/homozygosity for the A(TA)7TAA
polymorphism of the UGT1A1 gene, implying that a cause
and eﬀect relation may exist. In fact, the UDPG encoded by
the UGT1A1 gene plays an important role in the handling of
anionic substances in general, and in bilirubin elimination in
particular. Furthermore, UDPG acts on glucuronidation and
formation of bile salts [7].
It has long been recognised that the clinical sequence
of reduced UGT1A1 expression and activity of the relevant
enzyme is Gilbert syndrome with diverse percentages in
diﬀerent populations. Indeed, a previous study has shown
that DNA polymorphisms of extra TA nucleotides in the
repetitive TATAA box of the promoter region of UGT1A1
gene in Greek population are prevalent [8].
Numerous studies have tried to clarify the underlying
pathogenesisofcfx-inducedpseudolithiasis[6,9].Beginning
with the chemical composition of ﬁne lithogenic precipita-
tions, it should be stated that they are mainly consisted of
cholesterol monohydrate and calcium bilirubinate. It is also
known that cholesterol precipitates when the cholesterol-
solubilizing power of bile acid mixed micelles and phos-
pholipid vesicles is overwhelmed. In addition, bilirubin is
excretedasasolublediglucuronideanddeconjugation,either
by nonenzymatic hydrolysis or by P-glucuronidase, results
in free bilirubin. When the solubility product of calcium
and unconjugated bilirubin is exceeded, calcium bilirubinate
precipitates [10].
Nevertheless, how cfx has been involved in these mech-
anisms remains an unanswered question. This drug is a
small, anionic, negatively charged organic molecule, mainlyCase Reports in Medicine 3
eliminated in the urine, and to a lesser extent (40%) excreted
into bile [11]. Physicochemically, it is expected that when
the solubility product of calcium and cfx is exceeded,
precipitation should follow. Precipitation of a drug or a
xenobiotic in the biliary system is rarely seen; however, as cfx
is an organic anion, it behaves like other calcium-sensitive
anionsinbile(carbonate,bilirubinate,phosphate,palmitate)
that are implicated in the pathogenesis of gallstones [10].
It has been found that cfx and bile acids share a common
mechanism for hepatic transport and biliary excretion. It has
also been proved that high doses of cfx are more likely to
cause pseudolithiasis [9]. However, only a part of patients
treated with the maximum dose develop pseudolithiasis,
while pseudolithiasis has also been observed in lower doses
[10].Ontheotherhand,consideringthatthedrug’shandling
in all patients follows a deﬁned process, and what is more,
the infectious agent itself does not seem to deter the physic-
ochemical consistency and properties of the drug, but only
aﬀects the volume distribution and tissue penetration, we
assume that the factor determining the biliary sludge forma-
tion is not the infection. As a consequence, the fact that only
a number of cfx-treatedpatients is subjectto gallbladderpre-
cipitations indicates that predisposed individuals do exist. In
addition, as there are no statistically important diﬀerences in
thecharacteristicsandphenotypesoftheaﬀectedgroup(age,
gender, etc.), the diﬀerentiating factor in this clinical expres-
sion must be hidden in patients’ genes. For this reason, we
have already begun a prospective study in which we follow-
up children hospitalised in our department and treated with
cfx, studying with molecular analysis the genomic regions
with high incidence of the UGT1A1 gene polymorphisms.
In conclusion, we presented three patients with cfx-
induced pseudolithiasis and provided suggestions for this
occurrence among which the reduced function of UDPG
due to UGT1A1 gene polymorphisms seems to be the most
compatible.
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